Evidence map›Paper›PMID 31237465›Full record

ArticleToxicology mechanisms and methods2019

Development of an acute, short-term exposure model for phosgene.

Stephen T Hobson, Robert P Casillas, Richard A Richieri, Robert N Nishimura, Richard H Weisbart, Rick Tuttle, Glenn T Reynolds, Missag H Parseghian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology mechanisms and methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Special issue: emerging chemical terrorism threats.Toxicology mechanisms and methods · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Stephen T HobsonRubicon Biotechnology , Anaheim , CA , USA.
Robert P CasillasLatham BioPharm Group , Cambridge , MA , USA.
Richard A RichieriRubicon Biotechnology , Anaheim , CA , USA.
Robert N NishimuraUniversity of California, Los Angeles, School of Medicine , Los Angeles , CA , USA.
Richard H WeisbartUniversity of California, Los Angeles, School of Medicine , Los Angeles , CA , USA.
Rick TuttleMRIGlobal , Kansas City , MO , USA.
Glenn T ReynoldsRubicon Biotechnology , Anaheim , CA , USA.
Missag H ParseghianRubicon Biotechnology , Anaheim , CA , USA.ORCID http://orcid.org/0000-0001-6712-6925
Rubicon Biotechnology (United States) · USUniversity of California, Los Angeles · USMRIGlobal · US

Funding

Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalationR21ES024028 · NIEHS · RUBICON BIOTECHNOLOGY, INC. · PI NISHIMURA, ROBERT, PARSEGHIAN, MISSAG HAGOP · 2013 to 2014
$669k
NIEHS NIH HHS R21 ES024028
6 · The paper itself

Abstract

Phosgene is classified as a chemical warfare agent, yet data on its short-duration high concentration toxicity in a nose-only exposure rat model is sparse and inconsistent. Hence, an exposure system for short-term/high concentration exposure was developed and characterized. Herein, we report the median lethal concentration (LC

Indexed as

AnimalsChemical Warfare AgentsDose-Response Relationship, DrugInhalation ExposureLethal Dose 50LungMalePhosgenePulmonary EdemaRats, WistarSurvival AnalysisTime FactorsChemical Warfare AgentsPhosgeneacute toxicitydefense countermeasureslethal concentrationlethal dosePhosgenetoxic load exponenttoxic load model

Identifiers

PMID31237465
PMCPMC6715518
OpenAlexW2953816270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.